Your SlideShare is downloading. ×
Product Profiles: Alzheimers Disease - Immunotherapies can revolutionizetreatment paradigmPublished:November 2011No.Of Pag...
Table Of ContentsOVERVIEWCatalystSummaryEXECUTIVE SUMMARYStrategic scoping and focusDatamonitor key findingsRelated report...
Satisfaction of unmet needsClinical and commercial attractivenessGammagard (intravenous immunoglobulin; Baxter)Drug profil...
APPENDIX A – SURVEY INFORMATIONPhysician research methodologyPhysician sample breakdownThe survey questionnaireScreenerSec...
Table: Datamonitor’s drug assessment scorecard for bapineuzumab (Johnson &Johnson/Pfizer) in Alzheimer’s disease, 2011Tabl...
LIST OF FIGURESFigure: Datamonitor’s drug assessment summary for Alzheimer’s disease, 2011Figure: Aricept (donepezil; Eisa...
Figure:   Q13.2 Second line treatment of mild Alzheimer’s diseaseFigure:   Q14.1 First line treatment of moderate Alzheime...
Upcoming SlideShare
Loading in...5
×

Product profiles alzheimer's disease immunotherapies can revolutionize treatment paradigm

747

Published on

The beta-amyloid hypothesis has so far failed to deliver a viable candidate, contributing to an absence of new market entrants over the past decade. However, given the weight of candidates with disease-modifying potential in the pipeline, new drugs are expected to emerge that will satisfy one of the biggest unmet needs in the industry – a treatment that slows Alzheimer’s disease neurodegeneration.Market Research Reports, Market Research, Industry Analysis, Market Share, Market Size, marketing research,
Pharmaceutical Market Research,Pharmaceutical Market Research Reports,Pharmaceuticals Market Research,Pharmaceuticals Market Research Reports

Published in: Health & Medicine, Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
747
On Slideshare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
6
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Transcript of "Product profiles alzheimer's disease immunotherapies can revolutionize treatment paradigm"

  1. 1. Product Profiles: Alzheimers Disease - Immunotherapies can revolutionizetreatment paradigmPublished:November 2011No.Of Pages:150Price:US $ 11400IntroductionThe beta-amyloid hypothesis has so far failed to deliver a viable candidate, contributing toan absence of new market entrants over the past decade. However, given the weight ofcandidates with disease-modifying potential in the pipeline, new drugs are expected toemerge that will satisfy one of the biggest unmet needs in the industry – a treatment thatslows Alzheimer’s disease neurodegeneration.Features and benefits* Understand Datamonitor’s independent appraisal of marketed brands and key pipelineagents indicated for treating Alzheimer’s disease.* Illustrate how pipeline and marketed drugs compare to one another in terms of clinicaland commercial attributes.* Review important clinical developments for key pipeline agents with analysis of the latestclinical trial data.* Understand how marketed brands are positioned in the Alzheimer’s disease treatmentalgorithm.* Determine to what extent future therapies satisfy the main clinical unmet needs inAlzheimer’s disease treatment.Highlights* Datamonitor’s physician survey reveals that Aricept finds widespread use across all linesof therapy and severities, from mild cognitive impairment to severe Alzheimer’s disease.However, Eisai faces a steep decline in revenues as generic donepezil take hold in the US,marketed competition heightens in Japan, and European patents near expiry.* Bapineuzumab and solanezumab have the potential to revolutionize Alzheimer’s diseasetreatment and become future market leaders. However, each program carries a caveat.J&J/Pfizer are relying on post-hoc analyses of bapineuzumab in a subpopulation while Lilly isbetting on solanezumab’s Phase II biomarker effect translating into tangible benefits.* A precedent already exists for neurotransmitter mechanisms, ensuring a higher likelihoodof navigating through clinical trials. Late-stage symptomatic drugs include Eisai’s Ariceptpatch and GSK’s 5-HT6 receptor agonist SB-742457, although the potential rewards on offerfor these candidates are lower than for the immunotherapies.Browse All Pharmaceuticals Market Research Reports
  2. 2. Table Of ContentsOVERVIEWCatalystSummaryEXECUTIVE SUMMARYStrategic scoping and focusDatamonitor key findingsRelated reportsPRODUCT OVERVIEWProduct OverviewMarketed Alzheimer’s Disease Product ProfilesAricept (donepezil; Eisai/Pfizer)Drug profileDevelopment overviewSWOT analysisProduct positioningClinical and commercial attractivenessExelon (rivastigmine; Novartis)Drug profileDevelopment overviewSWOT analysisProduct positioningClinical and commercial attractivenessRazadyne (galantamine; Johnson & Johnson/Shire)Drug profileDevelopment overviewSWOT analysisProduct positioningClinical and commercial attractivenessNamenda (memantine; Forest/Merz/Lundbeck)Drug profileDevelopment overviewSWOT analysisProduct positioningClinical and commercial attractivenessPIPELINE PRODUCT PROFILESBapineuzumab (Johnson & Johnson/Pfizer)Drug profileDevelopment overviewSWOT analysisSatisfaction of unmet needsClinical and commercial attractivenessSolanezumab (LY2062430; Eli Lilly)Drug profileDevelopment overviewSWOT analysis
  3. 3. Satisfaction of unmet needsClinical and commercial attractivenessGammagard (intravenous immunoglobulin; Baxter)Drug profileDevelopment overviewSWOT analysisSatisfaction of unmet needsClinical and commercial attractivenessAricept patch (transdermal donepezil; Eisai/Teikoku Seiyaku)Drug profileDevelopment overviewSWOT analysisSatisfaction of unmet needsClinical and commercial attractivenessSB-742457 (GlaxoSmithKline)Drug profileDevelopment overviewSWOT analysisSatisfaction of unmet needsClinical and commercial attractivenessOther key disease-modifying drugs in development for Alzheimer’s diseaseACC-001 (conjugate beta-amyloid vaccine; Johnson & Johnson/Pfizer)AD02 (beta-amyloid vaccine; GlaxoSmithKline/Affiris)Avagacestat (BMS-708163; Bristol-Myers Squibb)CAD106 (beta-amyloid vaccine; Novartis/Cytos Biotechnology)CERE-110 (AAV2-NGF; Ceregene)CHF5074 (Chiesi Pharmaceuticals)Crenezumab (R7412/MABT5102A; Roche/AC Immune)Davunetide (AL-108; Allon Therapeutics)ELND005 (scyllo-inositol; Elan)EHT 0202 (etazolate; ExonHit Therapeutics)Gantenerumab (R1450; Roche/MorphoSys)Masitinib (AB1010; AB Science)NIC5-15 (Humanetics)Nypta (tideglusib; Noscira)Octagam (intravenous immunoglobulin; Octapharma)PF-04494700 (Pfizer/TransTech Pharma)PBT2 (Prana Biotechnology)Rember (methylthioninium chloride; TauRx Pharmaceuticals)T-817MA (Toyama Chemical)Other key symptomatic drugs in development for Alzheimer’s diseaseABT-288 (Abbott Laboratories)Dimebon (latrepirdine; Pfizer/Medivation)EVP-6124 (EnVivo Pharmaceuticals)GSK239512 (GlaxoSmithKline)Ispronicline (AZD3480; AstraZeneca/Targacept)Lu AE58054 (Lundbeck)BIBLIOGRAPHYJournal papersWebsitesDatamonitor reports
  4. 4. APPENDIX A – SURVEY INFORMATIONPhysician research methodologyPhysician sample breakdownThe survey questionnaireScreenerSection 10: Alzheimer’s disease regimensSection 11: Treated disease stagesSection 12: Treatment flow – mild cognitive impairment due to Alzheimer’s diseaseSection 13: Treatment flow – mild Alzheimer’s diseaseSection 14: Treatment flow – moderate Alzheimer’s diseaseSection 15: Treatment flow – severe Alzheimer’s diseaseAPPENDIX BPharmaVitae Explorer databaseDatamonitor drug assessment scorecardContributing expertsConferences attendedReport methodologyLIST OF TABLESTable: Key marketed and pipeline products for Alzheimer’s disease, 2011Table: Aricept (donepezil; Eisai/Pfizer) – drug profile in Alzheimer’s disease, 2011Table: Overview of pivotal trial data for Aricept (donepezil; Eisai/Pfizer) in Alzheimer’sdisease, 2011Table: Datamonitor’s drug assessment scorecard for Aricept (donepezil; Eisai/Pfizer) inAlzheimer’s disease, 2011Table: Exelon (rivastigmine; Novartis) – drug profile in Alzheimer’s disease, 2011Table: Overview of pivotal trial data for Exelon (rivastigmine; Novartis) in Alzheimer’sdisease, 2011Table: Datamonitor’s drug assessment scorecard for Exelon (Novartis) in Alzheimer’sdisease, 2011Table: Razadyne (galantamine; Johnson & Johnson/Shire) – drug profile in Alzheimer’sdisease, 2011Table: Overview of pivotal trial data for Razadyne (galantamine; Johnson & Johnson/Shire)in Alzheimer’s disease, 2011Table: Datamonitor’s drug assessment scorecard for Razadyne (galantamine; Johnson &Johnson/Shire) in Alzheimer’s disease, 2011Table: Namenda (memantine; Forest/Merz/Lundbeck) – drug profile in Alzheimer’s disease,2011Table: Overview of pivotal trial data for Namenda (memantine; Forest/Merz/Lundbeck) inAlzheimer’s disease, 2011Table: Datamonitor’s drug assessment scorecard for Namenda in Alzheimer’s disease, 2011Table: Bapineuzumab (Johnson & Johnson/Pfizer ) – drug profile in Alzheimer’s disease,2011Table: Clinical trial summary for bapineuzumab (Johnson & Johnson/Pfizer) in Alzheimer’sdiseaseTable: Ongoing clinical development program for bapineuzumab (Johnson & Johnson/Pfizer)in Alzheimer’s disease, 2011Table: Bapineuzumab (Johnson & Johnson/Pfizer) versus comparator therapy Aricept(donepezil; Eisai/Pfizer), the minimum acceptable product profile, and the target productprofile in Alzheimer’s disease, 2011
  5. 5. Table: Datamonitor’s drug assessment scorecard for bapineuzumab (Johnson &Johnson/Pfizer) in Alzheimer’s disease, 2011Table: Solanezumab (LY2062430; Eli Lilly ) – drug profile in Alzheimer’s disease, 2011Table: Ongoing clinical development program for solanezumab (LY2062430; Eli Lilly) inAlzheimer’s disease, 2011Table: Solanezumab (LY2062430; Eli Lilly) versus comparator therapy Aricept (donepezil;Eisai/Pfizer), the minimum acceptable product profile, and the target product profile inAlzheimer’s disease, 2011Table: Datamonitor’s drug assessment scorecard for solanezumab (Eli Lilly) in Alzheimer’sdisease, 2011Table: Gammagard (intravenous immunoglobulin; Baxter ) – drug profile in Alzheimer’sdisease, 2011Table: Key facts: Phase III trial of Gammagard, 2011Table: Gammagard (intravenous immunoglobulin; Baxter) versus comparator therapyAricept (donepezil; Eisai/Pfizer), the minimum acceptable product profile, and the targetproduct profile in Alzheimer’s disease, 2011Table: Datamonitor’s drug assessment scorecard for Gammagard (intravenousimmunoglobulin; Baxter) in Alzheimer’s disease, 2011Table: Aricept patch (transdermal donepezil; Eisai/Teikoku Seiyaku ) – drug profile inAlzheimer’s disease, 2011Table: Aricept patch (transdermal donepezil; Eisai/Teikoku Seiyaku) versus comparatortherapy Aricept (donepezil; Eisai/Pfizer), the minimum acceptable product profile, and thetarget product profile in Alzheimer’s disease, 2011Table: Datamonitor’s drug assessment scorecard for the Aricept patch (transdermaldonepezil; Eisai/Teikoku Seiyaku) in Alzheimer’s disease, 2011Table: SB-742457 (GlaxoSmithKline ) – drug profile in Alzheimer’s disease, 2011Table: Clinical trial summary for SB-742457 (GlaxoSmithKline) in Alzheimer’s diseaseTable: SB-742457 (GlaxoSmithKline) versus comparator therapy Aricept (donepezil;Eisai/Pfizer), the minimum acceptable product profile, and the target product profile inAlzheimer’s disease, 2011Table: Datamonitor’s drug assessment scorecard for SB-742457 in Alzheimer’s disease,2011Table: ACC-001: ongoing studies for the treatment of Alzheimer’s disease, 2011Table: Key facts: Phase II trial of AD02 (GlaxoSmithKline/Affiris), 2011Table: Key facts: Phase II trial of avagacestat (BMS-708163; Bristol-Myers Squibb), 2011Table: Key facts: Phase II trial of CERE-110, 2011Table: Key facts: Phase II trial of crenezumab (Roche/AC Immune), 2011Table: Key facts: Phase II trial of gantenerumab (R1450; Roche/MorphoSys), 2011Table: Key facts: Phase II trial of Nypta (tideglusib; Noscira), 2011Table: Key facts: Phase II trial of Octagam, 2011Table: Key facts: Phase II trial of PF-04494700, 2010Table: Key facts: Phase II trial of T-817MA, 2011Table: Key facts: Phase II trial of ABT-288, 2011Table: Key facts: Phase II trial of EVP-6124, 2011Table: Key facts: Phase II trial of GSK239512, 2010Table: Key facts: Phase II trial of Lu AE58054, 2010Table: Neurologists surveyed regarding Alzheimer’s disease across the seven majormarkets, 2011Table: Datamonitor’s drug assessment parameters for key Alzheimer’s disease therapies
  6. 6. LIST OF FIGURESFigure: Datamonitor’s drug assessment summary for Alzheimer’s disease, 2011Figure: Aricept (donepezil; Eisai/Pfizer) – SWOT analysis for Alzheimer’s disease, 2011Figure: Aricept (donepezil; Eisai/Pfizer) use by line of therapy and disease severity in theseven major markets, 2011Figure: Datamonitor’s drug assessment summary for Aricept (donepezil; Eisai/Pfizer) inAlzheimer’s disease, 2011Figure: Exelon (rivastigmine; Novartis) – SWOT analysis for Alzheimer’s disease, 2011Figure: Exelon (rivastigmine; Novartis) use by line of therapy and disease severity in theseven major markets, 2011Figure: Datamonitor’s drug assessment summary for Exelon (rivastigmine; Novartis) inAlzheimer’s disease, 2011Figure: Razadyne (galantamine; Johnson & Johnson/Shire) – SWOT analysis for Alzheimer’sdisease, 2011Figure: Razadyne (galantamine; Johnson & Johnson/Shire) use by line of therapy anddisease severity in the seven major markets, 2011Figure: Datamonitor’s drug assessment summary for Razadyne i(galantamine; Johnson &Johnson/Shire) n Alzheimer’s disease, 2011Figure: Namenda (memantine; Forest/Merz/Lundbeck) – SWOT analysis for Alzheimer’sdisease, 2011Figure: Namenda (memantine; Forest/Merz/Lundbeck) use by line of therapy and diseaseseverity in the seven major markets, 2011Figure: Datamonitor’s drug assessment summary for Namenda in Alzheimer’s disease, 2011Figure: Bapineuzumab (Johnson & Johnson/Pfizer) – SWOT analysis for Alzheimer’s disease,2011Figure: Datamonitor’s drug assessment summary for bapineuzumab (Johnson &Johnson/Pfizer) in Alzheimer’s disease, 2011Figure: Solanezumab (LY2062430; Eli Lilly) – SWOT analysis for Alzheimer’s disease, 2011Figure: Datamonitor’s drug assessment summary for solanezumab (Eli Lilly) in Alzheimer’sdisease, 2011Figure: Phase II Gammagard clinical trial design and resultsFigure: Gammagard (intravenous immunoglobulin; Baxter) – SWOT analysis for Alzheimer’sdisease, 2011Figure: Datamonitor’s drug assessment summary for Gammagard (intravenousimmunoglobulin; Baxter) in Alzheimer’s disease, 2011Figure: Aricept patch (transdermal donepezil; Eisai/Teikoku Seiyaku) – SWOT analysis forAlzheimer’s disease, 2011Figure: Datamonitor’s drug assessment summary for the Aricept patch (transdermaldonepezil; Eisai/Teikoku Seiyaku) in Alzheimer’s disease, 2011Figure: Phase II SB-742457 dose-ranging trial design and resultsFigure: Phase II SB-742457 comparator trial with donepezil design and resultsFigure: SB-742457 (GlaxoSmithKline) – SWOT analysis for Alzheimer’s disease, 2011Figure: Datamonitor’s drug assessment summary for SB-742457 in Alzheimer’s disease,2011Figure: Phase II masitinib clinical trial design and resultsFigure: Phase II Dimebon clinical trial design and resultsFigure: Q12.1 First line treatment of mild cognitive impairment due to Alzheimer’s diseaseFigure: Q12.2 Second line treatment of mild cognitive impairment due to Alzheimer’sdiseaseFigure: Q13.1 First line treatment of mild Alzheimer’s disease
  7. 7. Figure: Q13.2 Second line treatment of mild Alzheimer’s diseaseFigure: Q14.1 First line treatment of moderate Alzheimer’s diseaseFigure: Q14.2 Second line treatment of moderate Alzheimer’s diseaseFigure: Q15.1 First line treatment of severe Alzheimer’s diseaseFigure: Q15.2 Second line treatment of severe Alzheimer’s diseaseFigure: The PharmaVitae ExplorerAbout Us:ReportsnReports is an online library of over 100,000+ market research reports and in-depthmarket research studies & analysis of over 5000 micro markets. We provide 24/7 online andoffline support to our customers. Get in touch with us for your needs of market researchreports.Follow us on Twitter: http://twitter.com/marketsreportsOur Facebook Page: http://www.facebook.com/pages/ReportsnReports/191441427571689Contact:Mr.Priyank7557 Rambler road,Suite727,Dallas,TX75231Tel: + 1 888 391 5441E-mail: sales@reportsandreports.comhttp://www.reportsnreports.comVisit our Market Research Blog

×